InotivNOTV
NOTV
About: Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Employees: 2,055
0
Funds holding %
of 6,790 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
3.43% less ownership
Funds ownership: 16.94% [Q2] → 13.51% (-3.43%) [Q3]
18% less funds holding
Funds holding: 57 [Q2] → 47 (-10) [Q3]
18% less capital invested
Capital invested by funds: $7.3M [Q2] → $5.97M (-$1.33M) [Q3]
64% less call options, than puts
Call options by funds: $16K | Put options by funds: $44K
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4
5%
upside
Avg. target
$4
5%
upside
High target
$4
5%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Frank Takkinen 64% 1-year accuracy 7 / 11 met price target | 5%upside $4 | Buy Upgraded | 30 Sept 2024 |
Financial journalist opinion
Based on 4 articles about NOTV published over the past 30 days
Neutral
Seeking Alpha
3 days ago
Inotiv, Inc. (NOTV) Q4 2024 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV ) Q4 2024 Earnings Conference Call December 3, 2024 4:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Operator Good day, everyone, and welcome to today's Inotiv Fiscal 2024 Fourth Quarter Financial Results. At this time, all participants are in a listen-only mode.
Neutral
GlobeNewsWire
3 days ago
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update
— Enhanced liquidity through issuance of Second Lien Notes — Obtained amendment to credit agreement and extended note payable — Fourth quarter fiscal 2024 revenue down 7.3% to $130.4 million — Full year fiscal 2024 revenue down 14.3% to $490.7 million — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q4 FY 2024”) and twelve months ("FY 2024") ended September 30, 2024.
Neutral
GlobeNewsWire
2 weeks ago
Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth
Neutral
GlobeNewsWire
2 weeks ago
Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market.
Neutral
GlobeNewsWire
2 months ago
Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity
WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount of 15% Senior Secured Second Lien PIK Notes due February 2027 (the “Second Lien Notes”), and warrants to purchase common shares, to certain investors in a private offering.
Neutral
GlobeNewsWire
3 months ago
Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference
WEST LAFAYETTE, Ind., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., Inotiv's President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the 8th Annual Lake Street Best Ideas Growth Conference on Thursday, September 12, 2024, in New York City.
Neutral
Seeking Alpha
3 months ago
Inotiv, Inc. (NOTV) Q3 2024 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV ) Q3 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Bob Yedid - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Matt Hewitt - Craig-Hallum Nelson Cox - Lake Street Capital Markets Dave Windley - Jefferies Eric Coldwell - Baird Operator Good day, everyone and welcome to this Inotiv Third Quarter Earnings Conference Call. [Operator Instructions] And it's now my pleasure to turn the floor over to Mr.
Negative
Zacks Investment Research
3 months ago
Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates
Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.07 per share a year ago.
Neutral
GlobeNewsWire
4 months ago
Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024
WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on Thursday, August 8, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
Positive
InvestorPlace
4 months ago
3 Breakout Stocks to Buy Before They Make Headlines
In the current volatile market, breakout stocks with sound growth potential are most important for those investors looking to maximize returns. The list includes three such standout companies that can deliver substantial gains.
Charts implemented using Lightweight Charts™